LUMERA Trademark

Trademark Overview

On Tuesday, July 12, 2022, a trademark application was filed for LUMERA with the United States Patent and Trademark Office. The USPTO has given the LUMERA trademark a serial number of 97499991. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, September 3, 2024. This trademark is owned by Fulgent Therapeutics LLC. The LUMERA trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:

Testing for medical diagnostic and treatment purposes, namely, pathology, genetic, and molecular medical testing for cancer and other cancer diagnostic, monitoring, and detection for medical diagnostic and treatment purposes

Testing for scientific research purposes, namely, pathology, genetic, and molecular medical testing for cancer and other cancer diagnostic, monitoring, and detection for scientific research purposes
lumera

General Information

Serial Number97499991
Word MarkLUMERA
Filing DateTuesday, July 12, 2022
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, September 3, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 23, 2024

Trademark Statements

Goods and ServicesTesting for medical diagnostic and treatment purposes, namely, pathology, genetic, and molecular medical testing for cancer and other cancer diagnostic, monitoring, and detection for medical diagnostic and treatment purposes
Goods and ServicesTesting for scientific research purposes, namely, pathology, genetic, and molecular medical testing for cancer and other cancer diagnostic, monitoring, and detection for scientific research purposes

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, May 1, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, May 1, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameFulgent Therapeutics LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressEl Monte, CA 91731
Party NameFulgent Therapeutics LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressTemple City, CA 91780

Trademark Events

Event DateEvent Description
Thursday, April 27, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, July 15, 2022NEW APPLICATION ENTERED
Tuesday, August 2, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, April 26, 2023ASSIGNED TO EXAMINER
Thursday, April 27, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, April 27, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, May 1, 2023EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Monday, May 1, 2023COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Monday, May 1, 2023NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Monday, May 1, 2023EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Monday, May 1, 2023EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Monday, May 1, 2023COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Monday, May 1, 2023EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Monday, May 1, 2023NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Friday, June 16, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 16, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 16, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 18, 2023NON-FINAL ACTION WRITTEN
Tuesday, July 18, 2023NON-FINAL ACTION E-MAILED
Tuesday, July 18, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 20, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 18, 2023ASSIGNED TO LIE
Monday, December 18, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 18, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, December 18, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 3, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 23, 2024PUBLISHED FOR OPPOSITION
Tuesday, January 23, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, February 22, 2024EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, July 23, 2024TTAB RELEASE CASE TO TRADEMARKS
Tuesday, July 30, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, June 3, 2024EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, July 30, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, July 30, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, July 30, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, July 30, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, September 3, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 17, 2024TEAS STATEMENT OF USE RECEIVED

Related Keywords

lumera cancer testing purposes diagnostic medical monitoring detection other scientific research